INCY Incyte Corp

Price (delayed)

$84.62

Market cap

$18.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.36

Enterprise value

$17.12B

Sector: Healthcare
Industry: Biotechnology

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug, ...

Highlights

The debt is down by 31% year-on-year and by 25% since the previous quarter
INCY's gross profit is up by 24% year-on-year and by 9% since the previous quarter
INCY's net income has dropped by 166% year-on-year but it is up by 12% since the previous quarter
INCY's EPS has shrunk by 165% YoY but it is up by 13% QoQ

Key stats

What are the main financial stats of INCY
Market
Shares outstanding
219.84M
Market cap
$18.6B
Enterprise value
$17.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.1
Price to sales (P/S)
6.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.42
Earnings
Revenue
$2.67B
EBIT
-$230.04M
EBITDA
-$178.24M
Free cash flow
-$311.98M
Per share
EPS
-$1.36
Free cash flow per share
-$1.43
Book value per share
$11.92
Revenue per share
$12.23
TBVPS
$14.83
Balance sheet
Total assets
$3.56B
Total liabilities
$949.65M
Debt
$34.86M
Equity
$2.61B
Working capital
$1.73B
Liquidity
Debt to equity
0.01
Current ratio
3.74
Quick ratio
3.62
Net debt/EBITDA
8.3
Margins
EBITDA margin
-6.7%
Gross margin
95.1%
Net margin
-11.1%
Operating margin
-9%
Efficiency
Return on assets
-9.2%
Return on equity
-12.7%
Return on invested capital
-23.1%
Return on capital employed
-7.9%
Return on sales
-8.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INCY stock price

How has the Incyte stock price performed over time
Intraday
0.52%
1 week
2.35%
1 month
5.97%
1 year
-16.96%
YTD
-2.71%
QTD
4.12%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$2.67B
Gross profit
$2.54B
Operating income
-$240.29M
Net income
-$295.7M
Gross margin
95.1%
Net margin
-11.1%
INCY's net income has dropped by 166% year-on-year but it is up by 12% since the previous quarter
Incyte's operating income has plunged by 157% YoY but it has increased by 22% from the previous quarter
The net margin has dropped by 154% year-on-year but it is up by 18% since the previous quarter
INCY's operating margin has dropped by 146% year-on-year but it is up by 29% since the previous quarter

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
P/E
N/A
P/B
7.1
P/S
6.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.42
INCY's EPS has shrunk by 165% YoY but it is up by 13% QoQ
The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 16.8 and 15% less than its last 4 quarters average of 8.3
INCY's equity is up by 9% since the previous quarter
INCY's P/S is 41% below its 5-year quarterly average of 11.7 and 13% below its last 4 quarters average of 7.9
Incyte's revenue has increased by 24% YoY and by 9% from the previous quarter

Efficiency

How efficient is Incyte business performance
The ROE has plunged by 166% YoY but it has grown by 12% from the previous quarter
INCY's return on assets has dropped by 163% year-on-year but it is up by 12% since the previous quarter
INCY's ROS has shrunk by 138% YoY but it is up by 23% QoQ
The ROIC has plunged by 137% YoY but it has increased by 22% from the previous quarter

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
The current ratio has contracted by 23% YoY but it has grown by 5% from the previous quarter
The company's quick ratio fell by 23% YoY but it rose by 4.9% QoQ
The debt is 99% smaller than the equity
The debt to equity has plunged by 50% from the previous quarter and by 50% YoY
The debt is down by 31% year-on-year and by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.